Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16

Virology

Volumn 421, Issue 1, 2011, Pages 19-27

  Woodworth, Craig D ^a   Diefendorf, Laura P ^a   Jette, David F ^a   Mohammed, Abdulmajid ^a   Moses, Michael A ^a   Searleman, Sylvia A ^a   Stevens, Dan A ^a   Wilton, Katelynn M ^a   Mondal, Sumona ^a  

^a CLARKSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Cervical cancer; Chemoprevention; Epidermal growth factor receptor; Erlotinib; Immortalization; Papillomavirus; Senescence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN E6; PROTEIN E7;

APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; E6 ONCOGENE; E7 ONCOGENE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; SENESCENCE; UTERINE CERVIX; VIRUS GENOME; VIRUS ONCOGENE;

APOPTOSIS; CELL TRANSFORMATION, VIRAL; CERVIX UTERI; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 80055077658     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.09.014     Document Type: Article

References (49)

1. Akerman G.S., Tolleson W.H., Brown K.L., Zyzak L.L., Mourateva E., Engin T.S., Basaraba A., Coker A.L., Creek K.E., Pirisi L. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 2001, 61(9):3837-3843.
2. Arbyn M., Ronco G., Cuzick J., Wentzensen N., Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int. J. Cancer 2009, 125(11):2489-2496.
3. Arias-Pulido H., Joste N., Chavez A., Muller C.Y., Dai D., Smith H.O., Verschraegen C.F. Absence of epidermal growth factor receptor mutations in cervical cancer. Int. J. Gynecol. Cancer 2008, 18(4):749-754.
4. Ben-Bassat H., Rosenbaum-Mitrani S., Hartzstark Z., Levitzki R., Chaouat M., Shlomai Z., Klein B.Y., Kleinberger-Doron N., Gazit A., Tsvieli R., Levitzki A. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J. Pharmacol. Exp. Ther. 1999, 290(3):1442-1457.
5. Budiyanto A., Bito T., Kunisada M., Ashida M., Ichihashi M., Ueda M. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J. Invest. Dermatol. 2003, 121(5):1088-1094.
6. Campo M.S., Roden R.B. Papillomavirus prophylactic vaccines: established successes, new approaches. J. Virol. 2010, 84(3):1214-1220.
7. Carter C.A., Kelly R.J., Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin. Investig. Drugs 2009, 18(12):1829-1842.
8. Chen H.X., Cleck J.N., Coelho R., Dancey J.E. Epidermal growth factor receptor inhibitors: current status and future directions. Curr. Probl. Cancer 2009, 33(4):245-294.
9. Genther Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 2005, 65(15):6534-6542.
10. Goncalves A., Fabbro M., Lhomme C., Gladieff L., Extra J.M., Floquet A., Chaigneau L., Carrasco A.T., Viens P. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol. Oncol. 2008, 108(1):42-46.
11. Gossage L., Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res. 2010, 16(7):1973-1978.
12. Halbert C.L., Demers G.W., Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 1991, 65(1):473-478.
13. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8(12):3905-3910.
14. Hotta K., Tabata M., Kiura K., Kozuki T., Hisamoto A., Katayama H., Takigawa N., Fujimoto N., Fujiwara K., Ueoka H., Tanimoto M. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Oncol. Rep. 2007, 17(2):313-317.
15. Iglesias M., Yen K., Gaiotti D., Hildesheim A., Stoler M.H., Woodworth C.D. Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1alpha. Oncogene 1998, 17(10):1195-1205.
16. Iyer R., Bharthuar A. A review of erlotinib-an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin. Pharmacother. 2010, 11(2):311-320.
17. Johnson K.A., Brown P.H. Drug development for cancer chemoprevention: focus on molecular targets. Semin. Oncol. 2010, 37(4):345-358.
18. Kersemaekers A.M., Fleuren G.J., Kenter G.G., Van den Broek L.J., Uljee S.M., Hermans J., Van de Vijver M.J. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 1999, 5(3):577-586.
19. Khan M.A., Canhoto A.J., Housley P.R., Creek K.E., Pirisi L. Glucocorticoids stimulate growth of human papillomavirus type 16 (HPV16)-immortalized human keratinocytes and support HPV16-mediated immortalization without affecting the levels of HPV16 E6/E7 mRNA. Exp. Cell Res. 1997, 236(1):304-310.
20. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target. Oncol. 2009, 4(2):107-119.
21. Ling Y.H., Li T., Yuan Z., Haigentz M., Weber T.K., Perez-Soler R. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol. Pharmacol. 2007, 72(2):248-258.
22. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350(21):2129-2139.
23. McKenzie N.D., Kobetz E.N., Hnatyszyn J., Twiggs L.B., Lucci J.A. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol. Oncol. 2010, 116(3):572-577.
24. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63(10):4417-4421.
25. Nogueira-Rodrigues A., do Carmo C.C., Viegas C., Erlich F., Camisao C., Fontao K., Lima R., Herchenhorn D., Martins R.G., Moralez G.M., Small I.A., Ferreira C.G. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin. Cancer Res. 2008, 14(19):6324-6329.
26. Normanno N., Bianco C., Strizzi L., Mancino M., Maiello M.R., De Luca A., Caponigro F., Salomon D.S. The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets 2005, 6(3):243-257.
27. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr. Opin. HIV AIDS 2009, 4(1):52-56.
28. Perez Rodrigo I., Albornoz Lopez R., Soto Rojas M., Fernandez Garcia I., Torres Degayon V. Effectiveness and safety of erlotinib in 2 patients with carcinoma of the cervix. Farm. Hosp. 2009, 33(2):96-99.
29. Rosenberger S., De-Castro Arce J., Langbein L., Steenbergen R.D., Rosl F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(15):7006-7011.
30. Sasieni P. Chemoprevention of cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2006, 20(2):295-305.
31. Schiffman M.H., Brinton L.A. The epidemiology of cervical carcinogenesis. Cancer 1995, 76(10 Suppl.):1888-1901.
32. Schilder R.J., Sill M.W., Lee Y.C., Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int. J. Gynecol. Cancer 2009, 19(5):929-933.
33. Sizemore N., Choo C.K., Eckert R.L., Rorke E.A. Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp. Cell Res. 1998, 244(1):349-356.
34. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin. Ther. 2005, 27(10):1513-1534.
35. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69(5):3185-3192.
36. Suprynowicz F.A., Krawczyk E., Hebert J.D., Sudarshan S.R., Simic V., Kamonjoh C.M., Schlegel R. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J. Virol. 2010, 84(20):10619-10629.
37. Vaidya A.P., Parnes A.D., Seiden M.V. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Curr. Treat. Options Oncol. 2005, 6(2):103-114.
38. Vlastos A.T., Schottenfeld D., Follen M. Biomarkers and their use in cervical cancer chemoprevention. Crit. Rev. Oncol. Hematol. 2003, 46(3):261-273.
39. von Knebel Doeberitz M., Rittmuller C., zur Hausen H., Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer 1992, 51(5):831-834.
40. William W.N., Heymach J.V., Kim E.S., Lippman S.M. Molecular targets for cancer chemoprevention. Nat. Rev. Drug Discov. 2009, 8(3):213-225.
41. Woodworth C.D., Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am. J. Pathol. 1993, 142(5):1544-1555.
42. Woodworth C., Secott T., Isom H.C. Transformation of rat hepatocytes by transfection with simian virus 40 DNA to yield proliferating differentiated cells. Cancer Res. 1986, 46(8):4018-4026.
43. Woodworth C.D., Bowden P.E., Doniger J., Pirisi L., Barnes W., Lancaster W.D., DiPaolo J.A. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA. Cancer Res. 1988, 48(16):4620-4628.
44. Woodworth C.D., Notario V., DiPaolo J.A. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J. Virol. 1990, 64(10):4767-4775.
45. Woodworth C.D., Waggoner S., Barnes W., Stoler M.H., DiPaolo J.A. Human cervical and foreskin epithelial cells immortalized by human papillomavirus DNAs exhibit dysplastic differentiation in vivo. Cancer Res. 1990, 50(12):3709-3715.
46. Woodworth C.D., Cheng S., Simpson S., Hamacher L., Chow L.T., Broker T.R., DiPaolo J.A. Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 1992, 7(4):619-626.
47. Woodworth C.D., McMullin E., Iglesias M., Plowman G.D. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92(7):2840-2844.
48. Woodworth C.D., Gaiotti D., Michael E., Hansen L., Nees M. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized keratinocytes. Cancer Res. 2000, 60(16):4397-4402.
49. Woodworth C.D., Michael E., Marker D., Allen S., Smith L., Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol. Cancer Ther. 2005, 4(4):650-658.